Ascletis, CR Pharmaceutical partner to distribute HCV drug in Beijing

Ascletis Pharma Inc. (Hangzhou, China) partnered with the CR Pharmaceutical Commercial Group Co. Ltd. subsidiary of China Resources Pharmaceutical Group Ltd. (Beijing, China) to develop distribution networks and end-user services in Beijing for the launch of Ganovo danoprevir. China approved the HCV NS3/4A protease inhibitor in June to treat HCV infection (see “Chinese Approval for Ascletis’ HCV Drug")...